Telix Non Current Liabilities Total from 2010 to 2025
| TLX Stock | 17.24 0.27 1.54% |
Non Current Liabilities Total | First Reported 2011-06-30 | Previous Quarter 92 M | Current Value 617.3 M | Quarterly Volatility 110 M |
Check Telix Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Telix Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 10.9 M, Interest Expense of 38.3 M or Selling General Administrative of 123.5 M, as well as many indicators such as Price To Sales Ratio of 8.16, Days Sales Outstanding of 70.39 or Average Payables of 1.8 M. Telix financial statements analysis is a perfect complement when working with Telix Pharmaceuticals Valuation or Volatility modules.
Telix | Non Current Liabilities Total |
Latest Telix Pharmaceuticals' Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of Telix Pharmaceuticals Limited over the last few years. It is Telix Pharmaceuticals' Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Telix Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
| Timeline |
Telix Non Current Liabilities Total Regression Statistics
| Arithmetic Mean | 102,003,802 | |
| Geometric Mean | 19,281,541 | |
| Coefficient Of Variation | 205.62 | |
| Mean Deviation | 132,683,712 | |
| Median | 7,138,826 | |
| Standard Deviation | 209,743,455 | |
| Sample Variance | 43992.3T | |
| Range | 643.8M | |
| R-Value | 0.67 | |
| Mean Square Error | 25990.7T | |
| R-Squared | 0.45 | |
| Significance | 0 | |
| Slope | 29,506,454 | |
| Total Sum of Squares | 659884.8T |
Telix Non Current Liabilities Total History
About Telix Pharmaceuticals Financial Statements
Telix Pharmaceuticals investors use historical fundamental indicators, such as Telix Pharmaceuticals' Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Telix Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Total | 617.3 M | 648.2 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.